»» Public Issue Open: June 23, 2008 to June 25, 2008
»» Public Issue Type: 100% Book Built Issue (Initial Public Offer IPO)
»» Public Issue Size: 5,19,17,000 Equity Shares of Rs. 10/-
»» Face Value: Rs. 10/-
»» Public Issue Price: Rs 240/- to Rs 255/-
»» Maximum Subscription Amount for Retail Investor: Rs 100,000/-
»» Listing: BSE, NSE
»» Lead Manager: Kotak Mahindra, IDFC-SSKI, Morgan Stanley & Edelweiss Capital Ltd
»» Registrar: Karvy Computershare Pvt Ltd
(Ph: +91-40-23420815 Email: mrvs@karvy.com)
Search Stock Exchange News & Tips
Custom Search
Subscribe to:
Post Comments (Atom)
LinkWithin
Popular Posts
-
Bank of America is trying to figure out the regulatory barriers in doing business with India's largest private company Reliance Industri... -
SBI Bonds 2011 is going to list on the Exchanges effective from Wednesday, March 23, 2011 in the list of "F GROUP". SBI Bonds Seri...
-
Mumbai: Netherlands-based Rabobank Nederland announced on Friday that it had received permission from the Reserve Bank of India (RBI) to s...
-
Erasing its opening session gains, the Bombay Stock Exchange benchmark lost over 80 points during the pre-close session on Tuesday due to pr...
-
In what comes as a major setback to Infosys Technologies , board member TV Mohandas Pai has resigned, the company said in its press release ... -
Indian stock markets continued to trade marginally in the red in the afternoon trading session on Thursday. At 2.30 pm, the Nifty stood ...
-
The key benchmark indices surged, snapping four days' losses as world stocks rose and as a slide in crude oil prices from 2-1/2-year pea...
-
The 50-share Nifty index slipped to its 2-month low on Thursday, breaking key technical support levels of 5150 on weak global cues. "De...
-
The existing stringent merger and acquisition rules will be eased in the new telecom policy that will be in place by the year-end, communica... -
The Sensex ended in the negative terrain led by banking, metal and consumer goods stocks. Sustained selling was seen across board. Equities ...
1 comment:
Thanks. I am regularly following you. Your posts always contain some good information and your way of explanations is very very good. See marksans pharma news
Post a Comment